Previous 10 |
WALTHAM, MA / ACCESSWIRE / May 8, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company") today announced financial results for the quarter ended March 31, 2019 and provided an update on recent corporate and operational activities. Stephen From, EyeGate's Chief Exec...
WALTHAM, MA / ACCESSWIRE / May 2, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (''EyeGate'' or ''the Company'') announced today it has successfully submitted the Investigational Device Exemption (''IDE'') to the U.S. Food and Drug Administration (''FDA") regarding its photorefractive ...
EyeGate Pharmaceuticals (NASDAQ: EYEG ) has met with the FDA regarding its Ocular Bandage Gel ("OBG") product and has confirmed its path to a de novo filing. More news on: EyeGate Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
WALTHAM, MA / ACCESSWIRE / March 26, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or "the Company") has met with the U.S. Food and Drug Administration ("FDA") regarding its Ocular Bandage Gel ("OBG") product and has confirmed its path to a de novo filing. The FDA has agreed...
EyeGate Pharmaceuticals (NASDAQ: EYEG ) announces 2018 results. Highlights: More news on: EyeGate Pharmaceuticals, Healthcare stocks news, Earnings news and commentary, , Read more ...
WALTHAM, MA / ACCESSWIRE / March 1, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (''EyeGate'' or ''the Company'') today announced financial results for the year ended December 31, 2018 and provided an update on recent corporate and operational activities. Stephen From, EyeGate's Chie...
WALTHAM, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) today announced that the Company will attend and present at the 21 st BIO CEO & Investor Conference being held in New York, NY at the ...
News, Short Squeeze, Breakout and More Instantly...
Eyegate Pharmaceuticals Inc. Company Name:
EYEG Stock Symbol:
NASDAQ Market:
LONDON, UK / ACCESSWIRE / December 9, 2022 / Kazia Therapeutics has announced the publication of pre-clinical data for its second pipeline asset, EVT801 in the journal Cancer Research Communications. The research was conducted by licensing partner Evotec and was the key driver for Kazia in-licen...
LONDON, UK / ACCESSWIRE / December 7, 2022 / With its H123 interim results, ReNeuron highlighted progress across its proprietary exosome platform, CustomEx. The company reported H123 revenues of £438k (H122: £58k), primarily related to income associated with a £320k payment from F...
WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announc...